The need for differentiating diabetes-specific mortality from total mortality when comparing metformin with insulin regarding cancer survival

Acta Diabetol. 2017 Feb;54(2):219-220. doi: 10.1007/s00592-016-0933-2. Epub 2016 Oct 28.

Authors

Min Wei^{1

2}, Yu Liu³, Chunhong Wang², Chuanhua Yu², Dejia Li², Wei Zhou², Zhi-Jiang Zhang²

Affiliations

¹ Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, China.
² Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan, China.
³ Department of Statistics and Public Administration, College of Management, Wuhan Institute of Technology, 206 Optical Valley Road, Wuhan, China. lyu429@163.com.

PMID: 27796654
DOI: 10.1007/s00592-016-0933-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Diabetes Mellitus, Type 2
Humans
Hypoglycemic Agents
Insulin*
Metformin*
Neoplasms

Substances

Hypoglycemic Agents
Insulin
Metformin